Anti-MUC1 antibody or antigen-binding fragment thereof, and use thereof

By designing anti-MUC1 antibodies or their antigen-binding fragments with specific amino acid sequences, the problems of insufficient target specificity and cell internalization efficiency of existing antibodies have been solved, achieving efficient recognition and internalization of MUC1 in tumor cells, which is applicable to the diagnosis and treatment of MUC1-related cancers.

WO2026145796A1PCT designated stage Publication Date: 2026-07-09DUALITY BIOLOGICS (SUZHOU) CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
DUALITY BIOLOGICS (SUZHOU) CO LTD
Filing Date
2026-01-05
Publication Date
2026-07-09

AI Technical Summary

Technical Problem

Existing anti-MUC1 antibodies are insufficient in terms of target specificity and cell internalization efficiency, making it difficult to effectively recognize and internalize MUC1 proteins in tumor cells, especially abnormally glycosylated MUC1.

Method used

An anti-MUC1 antibody or its antigen-binding fragment has been developed, containing specific HCDR and LCDR amino acid sequences, which can efficiently recognize and bind to the tumor-specific glycosylated modified antigen STn-MUC1 while maintaining the basic recognition ability of the MUC1 protein backbone.

Benefits of technology

This antibody exhibits good binding specificity and internalization ability in tumor cells, especially in tumor cells with high MUC1 expression such as NCI-H1975 and OVCAR3, showing significant internalization ability, and is suitable for the diagnosis and treatment of MUC1-related cancers.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2026070605_09072026_PF_FP_ABST
    Figure CN2026070605_09072026_PF_FP_ABST
Patent Text Reader

Abstract

Provided are an anti-MUC1 antibody or an antigen-binding fragment thereof, and the use thereof. The MUC1 antibody or the antigen-binding fragment thereof comprises a heavy chain variable region VH and a light chain variable region VL, wherein the heavy chain variable region VH comprises HCDRHCDR2 and HCDR3, and the light chain variable region VL comprises LCDR1, LCDR2 and LCDR3. The antibody exhibits good affinity for a tumor-specific MUC1 antigen, and has significant internalization ability toward cells expressing MUC1.
Need to check novelty before this filing date? Find Prior Art